The Kass lab focuses on elucidating new mechanisms and treatments for cardiac hypertrophy and failure.
Basic science investigations span an array of inquiries, such as understanding the basic mechanisms underlying cardiac dyssynchrony and resynchronization in the failing heart, and beneficial influences of nitric oxide/cGMP/protein kinase G and cGMP-targeted phosphdiesterase signaling cascades on cardiac maladaptive stress remodeling. Recently, the latter has particularly focused on the role of phosphodiesterase type 5 and its pharmacologic inhibitors (e.g. sildenafi, Viagra®), on myocyte signaling cascades modulated by protein kinase G, and on the nitric oxide synthase dysregulation coupled with oxidant stress.
The lab also conducts clinical research and is presently exploring new treatments for heart failure with a preserved ejection fraction, studying ventricular-arterial interaction and its role in adverse heart-vessel coupling in left heart failure and pulmonary hypertension, and testing new drug, device, and cell therapies for heart disease. A major theme has been with the use of advanced non-invasive and invasive catheterization-based methods to assess cardiac mechanics in patients.
what's new?
The cardiomyocyte is Master and Commander by its influence over TGFbeta signaling | 03/15/2014TGFbeta signaling in myocytes regulates post MI inflammatory changes and cardiac rupture Continue reading...
PKG and TRPC6 - major regulators of abnormal mechano-signaling in Muscular Dytrophy | 01.10/2014TRPC6 is major player in altered mechanosensing in muscular dystrophy and is targeted by PKG activation Continue reading...
recent publications
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. | 2013Sabba et al. | Circulation Heart Failure..html_link html_linkElectromechanical dyssynchrony and resynchronization of the failing heart. | 2013Kirk and Kass | Circ Res..html_link html_link